

# Jin-Ming Yu

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/446936/publications.pdf>

Version: 2024-02-01

233  
papers

4,988  
citations

101384

36  
h-index

155451

55  
g-index

236  
all docs

236  
docs citations

236  
times ranked

7302  
citing authors

#	ARTICLE	IF	CITATIONS
1	Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 87.	3.5	213
2	Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. <i>Cancer Letters</i> , 2018, 414, 166-173.	3.2	207
3	Redox homeostasis maintained by GPX4 facilitates STING activation. <i>Nature Immunology</i> , 2020, 21, 727-735.	7.0	188
4	Blocking the PD-1/PD-L1 pathway in glioma: a potential new treatment strategy. <i>Journal of Hematology and Oncology</i> , 2017, 10, 81.	6.9	114
5	Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte-associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer. <i>Translational Research</i> , 2015, 166, 721-732.e1.	2.2	95
6	The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. <i>Cancer Biology and Medicine</i> , 2019, 16, 655-670.	1.4	95
7	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. <i>Cancer Letters</i> , 2017, 405, 29-37.	3.2	93
8	The landscape of bispecific T cell engager in cancer treatment. <i>Biomarker Research</i> , 2021, 9, 38.	2.8	90
9	Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges. <i>Cancer Letters</i> , 2015, 365, 23-29.	3.2	84
10	Additional value of PET/CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1255-9.	2.8	83
11	ZBP1-MLKL necroptotic signaling potentiates radiation-induced antitumor immunity via intratumoral STING pathway activation. <i>Science Advances</i> , 2021, 7, eabf6290.	4.7	79
12	The prognostic significance of PD-L1 expression in patients with glioma: A meta-analysis. <i>Scientific Reports</i> , 2017, 7, 4231.	1.6	67
13	A good start of immunotherapy in esophageal cancer. <i>Cancer Medicine</i> , 2019, 8, 4519-4526.	1.3	67
14	The prognosis analysis of different metastasis pattern in patients with different breast cancer subtypes: a SEER based study. <i>Oncotarget</i> , 2017, 8, 26368-26379.	0.8	64
15	HMGB1 correlates with angiogenesis and poor prognosis of perihilar cholangiocarcinoma via elevating VEGFR2 of vessel endothelium. <i>Oncogene</i> , 2019, 38, 868-880.	2.6	62
16	Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. <i>Cancer Letters</i> , 2018, 418, 1-9.	3.2	61
17	Proton beam therapy for cancer in the era of precision medicine. <i>Journal of Hematology and Oncology</i> , 2018, 11, 136.	6.9	61
18	Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice. <i>Frontiers in Immunology</i> , 2020, 11, 1088.	2.2	61

#	ARTICLE	IF	CITATIONS
19	Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. <i>American Journal of Cancer Research</i> , 2015, 5, 2064-74.	1.4	60
20	MiR-216a-3p inhibits colorectal cancer cell proliferation through direct targeting COX2 and ALOX5. <i>Journal of Cellular Biochemistry</i> , 2018, 119, 1755-1766.	1.2	59
21	miR-375 inhibits cancer stem cell phenotype and tamoxifen resistance by degrading HOXB3 in human ER-positive breast cancer. <i>Oncology Reports</i> , 2017, 37, 1093-1099.	1.2	57
22	Boschniakia Rossica Polysaccharide Triggers Laryngeal Carcinoma Cell Apoptosis by Regulating Expression of Bcl-2, Caspase-3, and P53. <i>Medical Science Monitor</i> , 2017, 23, 2059-2064.	0.5	54
23	Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2019, 12, 67.	6.9	54
24	Early Change in Metabolic Tumor Heterogeneity during Chemoradiotherapy and Its Prognostic Value for Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0157836.	1.1	53
25	Integrative nomogram of CT imaging, clinical, and hematological features for survival prediction of patients with locally advanced non-small cell lung cancer. <i>European Radiology</i> , 2019, 29, 2958-2967.	2.3	52
26	Feasibility of Involved-Field Conformal Radiotherapy for Cervical and Upper-Thoracic Esophageal Cancer. <i>Onkologie</i> , 2011, 34, 599-604.	1.1	49
27	The postoperative neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after the complete resection of stage I non-small cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 6529-6537.	1.0	49
28	Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non-small cell lung cancer cells. <i>Chinese Journal of Cancer</i> , 2016, 35, 50.	4.9	48
29	Silencing METTL3 inhibits the proliferation and invasion of osteosarcoma by regulating ATAD2. <i>Biomedicine and Pharmacotherapy</i> , 2020, 125, 109964.	2.5	46
30	Epigallocatechin-3-gallate ameliorates radiation-induced acute skin damage in breast cancer patients undergoing adjuvant radiotherapy. <i>Oncotarget</i> , 2016, 7, 48607-48613.	0.8	45
31	Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 343-354.	2.0	42
32	CD8+/FOXP3+ ratio and PD-L1 expression associated with survival in pT3N0M0 stage esophageal squamous cell cancer. <i>Oncotarget</i> , 2016, 7, 71455-71465.	0.8	42
33	Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. <i>Melanoma Research</i> , 2019, 29, 77-84.	0.6	41
34	Can an <sup>18</sup> F-ALF-NOTA-PRGD2 PET/CT Scan Predict Treatment Sensitivity to Concurrent Chemoradiotherapy in Patients with Newly Diagnosed Glioblastoma?. <i>Journal of Nuclear Medicine</i> , 2016, 57, 524-529.	2.8	40
35	Expressions of CD8+TILs, PD-L1 and Foxp3+TILs in stage I NSCLC guiding adjuvant chemotherapy decisions. <i>Oncotarget</i> , 2016, 7, 64318-64329.	0.8	40
36	Clinical outcome of tyrosine kinase inhibitors alone or combined with radiotherapy for brain metastases from epidermal growth factor receptor (EGFR) mutant non small cell lung cancer (NSCLC). <i>Oncotarget</i> , 2017, 8, 13304-13311.	0.8	40

#	ARTICLE	IF	CITATIONS
37	Efficacy and Safety of Anti-PD-1 Plus Anlotinib in Patients With Advanced Non-Small-Cell Lung Cancer After Previous Systemic Treatment Failure—A Retrospective Study. <i>Frontiers in Oncology</i> , 2021, 11, 628124.	1.3	39
38	Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma. <i>Radiation Oncology</i> , 2014, 9, 64.	1.2	38
39	Significant efficacy and well safety of apatinib in an advanced liver cancer patient: a case report and literature review. <i>Oncotarget</i> , 2017, 8, 20510-20515.	0.8	37
40	Preoperative to postoperative change in neutrophil-to-lymphocyte ratio predict survival in colorectal cancer patients. <i>Future Oncology</i> , 2018, 14, 1187-1196.	1.1	37
41	The prognostic analysis of different metastatic patterns in extensive-stage small-cell lung cancer patients: a large population-based study. <i>Future Oncology</i> , 2018, 14, 1397-1407.	1.1	36
42	Involved-field radiotherapy for esophageal squamous cell carcinoma: theory and practice. <i>Radiation Oncology</i> , 2016, 11, 18.	1.2	34
43	Prognostic value of dynamic albumin-to-alkaline phosphatase ratio in limited stage small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 995-1006.	1.1	33
44	Combined treatment of non-small cell lung cancer using radiotherapy and immunotherapy: challenges and updates. <i>Cancer Communications</i> , 2021, 41, 1086-1099.	3.7	33
45	<sup>18</sup> F-alfatide PET/CT may predict short-term outcome of concurrent chemoradiotherapy in patients with advanced non-small cell lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2336-2342.	3.3	32
46	mRNA and methylation profiling of radioresistant esophageal cancer cells: the involvement of Sall2 in acquired aggressive phenotypes. <i>Journal of Cancer</i> , 2017, 8, 646-656.	1.2	32
47	PET/CT imaging-guided dose painting in radiation therapy. <i>Cancer Letters</i> , 2014, 355, 169-175.	3.2	31
48	Primary results from TAIL: a global single-arm safety study of atezolizumab monotherapy in a diverse population of patients with previously treated advanced non-small cell lung cancer. , 2021, 9, e001865.		31
49	Changes in Functional Lung Regions During the Course of Radiation Therapy and Their Potential Impact on Lung Dosimetry for Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 145-151.	0.4	30
50	Sprouty2 suppresses progression and correlates to favourable prognosis of intrahepatic cholangiocarcinoma via antagonizing <sc>FGFR</sc>2 signalling. <i>Journal of Cellular and Molecular Medicine</i> , 2018, 22, 5596-5606.	1.6	30
51	Prognostic value of systemic immune-inflammation index in patients with advanced non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 2643-2650.	1.1	30
52	miR-608 and miR-4513 significantly contribute to the prognosis of lung adenocarcinoma treated with EGFR-TKIs. <i>Laboratory Investigation</i> , 2019, 99, 568-576.	1.7	30
53	Anti-EPD&L1/TGF&R fusion protein (SHR&1701) overcomes disrupted lymphocyte recovery&induced resistance to PD&1/PD&L1 inhibitors in lung cancer. <i>Cancer Communications</i> , 2022, 42, 17-36.	3.7	30
54	An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib. <i>Radiotherapy and Oncology</i> , 2020, 152, 96-100.	0.3	29

#	ARTICLE	IF	CITATIONS
55	Computed Tomography-Based Delta-Radiomics Analysis for Discriminating Radiation Pneumonitis in Patients With Esophageal Cancer After Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 443-455.	0.4	29
56	Nrf2 and Keap1 abnormalities in esophageal squamous cell carcinoma and association with the effect of chemoradiotherapy. <i>Thoracic Cancer</i> , 2018, 9, 726-735.	0.8	28
57	Prognostic value of delta inflammatory biomarker-based nomograms in patients with inoperable locally advanced NSCLC. <i>International Immunopharmacology</i> , 2019, 72, 395-401.	1.7	28
58	A review of radiation-induced lymphopenia in patients with esophageal cancer: an immunological perspective for radiotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592092682.	1.4	28
59	Clinical outcomes of immune checkpoint blockades and the underlying immune escape mechanisms in squamous and adenocarcinoma NSCLC. <i>Cancer Medicine</i> , 2021, 10, 3-14.	1.3	28
60	[18F]AIF-NOTA-FAPI-04 PET/CT uptake in metastatic lesions on PET/CT imaging might distinguish different pathological types of lung cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1671-1681.	3.3	28
61	Cetuximab in combination with chemoradiotherapy in Chinese patients with non-resectable, locally advanced esophageal squamous cell carcinoma: A prospective, multicenter phase II trial. <i>Radiotherapy and Oncology</i> , 2013, 109, 275-280.	0.3	27
62	Fucoidan Promotes Apoptosis and Inhibits EMT of Breast Cancer Cells. <i>Biological and Pharmaceutical Bulletin</i> , 2019, 42, 442-447.	0.6	27
63	[18F]AIF-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2761-2773.	3.3	26
64	The prognostic role of circulating CD8+ T cell proliferation in patients with untreated extensive stage small cell lung cancer. <i>Journal of Translational Medicine</i> , 2019, 17, 402.	1.8	25
65	Prognostic value of 3-Deoxy-18F-Fluorothymidine ([18F] FLT PET) in patients with recurrent malignant gliomas. <i>Nuclear Medicine and Biology</i> , 2014, 41, 710-715.	0.3	24
66	Intra-tumour <sup>18</sup> F-FDG uptake heterogeneity decreases the reliability on target volume definition with positron emission tomography/computed tomography imaging. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2015, 59, 338-345.	0.9	24
67	&lt;p&gt;Increased systemic immune-inflammation index independently predicts poor survival for hormone receptor-negative, HER2-positive breast cancer patients&lt;p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 3153-3162.	0.9	24
68	Radiotherapy for esophageal carcinoma: dose, response and survival. <i>Cancer Management and Research</i> , 2018, Volume 10, 13-21.	0.9	23
69	The Role of Radiation Oncology in Immuno-Oncology. <i>Oncologist</i> , 2019, 24, S42-S52.	1.9	23
70	Pretreatment PET/CT imaging of angiogenesis based on 18F-RGD tracer uptake may predict antiangiogenic response. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 940-947.	3.3	23
71	Current landscape and future directions of biomarkers for predicting responses to immune checkpoint inhibitors. <i>Cancer Management and Research</i> , 2018, Volume 10, 2475-2488.	0.9	22
72	The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non-small cell lung cancer—a retrospective study from one single cancer institute. <i>Cancer Medicine</i> , 2019, 8, 2769-2776.	1.3	22

#	ARTICLE	IF	CITATIONS
73	Calcium channel TRPV6 promotes breast cancer metastasis by NFATC2IP. <i>Cancer Letters</i> , 2021, 519, 150-160.	3.2	22
74	Value of <sup>18</sup> F-FDG PET-CT in surveillance of postoperative colorectal cancer patients with various carcinoembryonic antigen concentrations. <i>World Journal of Gastroenterology</i> , 2014, 20, 6608.	1.4	22
75	A Pilot Study of 18F-Alfatide PET/CT Imaging for Detecting Lymph Node Metastases in Patients with Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2017, 7, 2877.	1.6	21
76	A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1098-1106.	0.4	20
77	Radiation Recall Pneumonitis Induced by Anti-PD-1 Blockade: A Case Report and Review of the Literature. <i>Frontiers in Oncology</i> , 2020, 10, 561.	1.3	20
78	Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 81906-81917.	0.8	20
79	A Comparative Study of Noninvasive Hypoxia Imaging with 18F-Fluoroerythronitroimidazole and 18F-Fluoromisonidazole PET/CT in Patients with Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0157606.	1.1	19
80	The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer. <i>Oncotarget</i> , 2017, 8, 33736-33744.	0.8	19
81	A Novel Nomogram and Risk Classification System Predicting Radiation Pneumonitis in Patients With Esophageal Cancer Receiving Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 1074-1085.	0.4	19
82	Delineating the pattern of treatment for elderly locally advanced NSCLC and predicting outcomes by a validated model: A SEER based analysis. <i>Cancer Medicine</i> , 2019, 8, 2587-2598.	1.3	19
83	The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation. <i>Cancer Communications</i> , 2021, 41, 1314-1330.	3.7	19
84	C-Met as a Molecular Marker for Esophageal Squamous Cell Carcinoma and Its Association with Clinical Outcome. <i>Journal of Cancer</i> , 2016, 7, 587-594.	1.2	18
85	Preoperative radiation may improve the outcomes of resectable IIIA/N2 non-small cell lung cancer patients: A propensity score matching-based analysis from surveillance, epidemiology, and end results database. <i>Cancer Medicine</i> , 2018, 7, 4354-4360.	1.3	18
86	Association of Twice-Daily Radiotherapy With Subsequent Brain Metastases in Adults With Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2019, 2, e190103.	2.8	18
87	A Nomogram to Predict Distant Metastasis for Patients with Esophageal Cancer. <i>Oncology Research and Treatment</i> , 2020, 43, 2-9.	0.8	18
88	Osimertinib (AZD9291) increases radio-sensitivity in EGFR T790M non-small cell lung cancer. <i>Oncology Reports</i> , 2019, 41, 77-86.	1.2	17
89	Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 803247.	2.2	17
90	Slight advantages of nimotuzumab versus cetuximab plus concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma. <i>Cancer Biology and Therapy</i> , 2019, 20, 1121-1126.	1.5	16

#	ARTICLE	IF	CITATIONS
91	Neutrophil-to-lymphocyte ratio is superior to platelet-to-lymphocyte ratio as a prognostic predictor in advanced non-small-cell lung cancer treated with first-line platinum-based chemotherapy. <i>Future Oncology</i> , 2019, 15, 625-635.	1.1	16
92	Anti-PD-(L)1 immunotherapy for brain metastases in non-small cell lung cancer: Mechanisms, advances, and challenges. <i>Cancer Letters</i> , 2021, 502, 166-179.	3.2	16
93	Evaluation of factors associated with platinum-sensitivity status and survival in limited-stage small cell lung cancer patients treated with chemoradiotherapy. <i>Oncotarget</i> , 2017, 8, 81405-81418.	0.8	16
94	Validation study for the hypothesis of internal mammary sentinel lymph node lymphatic drainage in breast cancer. <i>Oncotarget</i> , 0, 7, 41996-42006.	0.8	16
95	Incorporation of circulating tumor cells and whole-body metabolic tumor volume of 18F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2018, 30, 596-604.	0.7	16
96	The Value of CBCT-based Tumor Density and Volume Variations in Prediction of Early Response to Chemoradiation Therapy in Advanced NSCLC. <i>Scientific Reports</i> , 2017, 7, 14650.	1.6	15
97	FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, e111-e119.	1.1	14
98	Postoperative radiation in esophageal squamous cell carcinoma and target volume delineation. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4187-4196.	1.0	14
99	The expression of p62 and nuclear Nrf2 in esophageal squamous cell carcinoma and association with radioresistance. <i>Thoracic Cancer</i> , 2020, 11, 130-139.	0.8	14
100	Clinical implications of germline BCL2L1 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy. <i>Lung Cancer</i> , 2021, 151, 39-43.	0.9	14
101	GINS2 attenuates the development of lung cancer by inhibiting the STAT signaling pathway. <i>Journal of Cancer</i> , 2021, 12, 99-110.	1.2	14
102	Overlap time is an independent risk factor of radiation pneumonitis for patients treated with simultaneous EGFR-TKI and thoracic radiotherapy. <i>Radiation Oncology</i> , 2021, 16, 41.	1.2	14
103	Intrapericardial bevacizumab safely and effectively treats malignant pericardial effusion in advanced cancer patients. <i>Oncotarget</i> , 2016, 7, 52436-52441.	0.8	13
104	Extended field intensity-modulated radiotherapy plus concurrent nedaplatin treatment in cervical cancer. <i>Oncology Letters</i> , 2016, 11, 3421-3427.	0.8	13
105	Risk factors for brain metastases after prophylactic cranial irradiation in small cell lung cancer. <i>Scientific Reports</i> , 2017, 7, 42743.	1.6	13
106	Real-World Data on Apatinib Efficacy - Results of a Retrospective Study in Metastatic Breast Cancer Patients Pretreated With Multiline Treatment. <i>Frontiers in Oncology</i> , 2021, 11, 643654.	1.3	13
107	Greater efficacy of intracavitary infusion of bevacizumab compared to traditional local treatments for patients with malignant cavity serous effusion. <i>Oncotarget</i> , 2017, 8, 35262-35271.	0.8	13
108	The impact of intratumoral metabolic heterogeneity on postoperative recurrence and survival in resectable esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 14969-14977.	0.8	13



#	ARTICLE	IF	CITATIONS
109	False-positive diagnosis of disease progression by magnetic resonance imaging for response assessment in prostate cancer with bone metastases: A case report and review of the pitfalls of images in the literature. <i>Oncology Letters</i> , 2015, 10, 3585-3590.	0.8	12
110	A functional BRCA1 coding sequence genetic variant contributes to prognosis of triple-negative breast cancer, especially after radiotherapy. <i>Breast Cancer Research and Treatment</i> , 2017, 166, 109-116.	1.1	12
111	Comparison of predictive powers of functional and anatomic dosimetric parameters for radiation-induced lung toxicity in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2018, 129, 242-248.	0.3	12
112	Dosimetric and Radiobiological Comparison of External Beam Radiotherapy Using Simultaneous Integrated Boost Technique for Esophageal Cancer in Different Location. <i>Frontiers in Oncology</i> , 2019, 9, 674.	1.3	12
113	&lt;p&gt;Primary tumor location is an important predictor of survival in pulmonary adenocarcinoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2269-2280.	0.9	12
114	A<sub>2A</sub>R Antagonism with DZD2269 Augments Antitumor Efficacy of Irradiation in Murine Model. <i>Journal of Cancer</i> , 2020, 11, 3685-3692.	1.2	12
115	Taxifolin Targets PI3K and mTOR and Inhibits Glioblastoma Multiforme. <i>Journal of Oncology</i> , 2021, 2021, 1-12.	0.6	12
116	Correlation of CD146 expression and clinicopathological characteristics in esophageal squamous cell carcinoma. <i>Oncology Letters</i> , 2014, 8, 859-863.	0.8	11
117	Circulating Tumor Cells Correlate with Recurrence in Stage III Small-cell Lung Cancer after Systemic Chemoradiotherapy and Prophylactic Cranial Irradiation. <i>Japanese Journal of Clinical Oncology</i> , 2014, 44, 948-955.	0.6	11
118	Association between serum tumor markers and metabolic tumor volume or total lesion glycolysis in patients with recurrent small cell lung cancer. <i>Oncology Letters</i> , 2015, 10, 3123-3128.	0.8	11
119	Positive Effect of Higher Adult Body Mass Index on Overall Survival of Digestive System Cancers Except Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2017, 2017, 1-15.	0.9	11
120	Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer. <i>Journal of Cancer</i> , 2017, 8, 3190-3197.	1.2	11
121	Enhanced efficacy of AZD3759 and radiation on brain metastasis from EGFR mutant non&small cell lung cancer. <i>International Journal of Cancer</i> , 2018, 143, 212-224.	2.3	11
122	Prognostic Value of Metabolic Parameters of Metastatic Lymph Nodes on 18F-FDG PET/CT in Patients With Limited-stage Small-cell Lung Cancer With Lymph Node Involvement. <i>Clinical Lung Cancer</i> , 2018, 19, e101-e108.	1.1	11
123	Male patients with resected IIIA-N2 non-small-cell lung cancer may benefit from postoperative radiotherapy: a population-based survival analysis. <i>Future Oncology</i> , 2018, 14, 2371-2381.	1.1	11
124	Clinical and radiological characteristics of central pulmonary adenocarcinoma: a comparison with central squamous cell carcinoma and small cell lung cancer and the impact on treatment response. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 2509-2517.	1.0	11
125	Risk Factors Associated with Precancerous Lesions of Esophageal Squamous Cell Carcinoma: a Screening Study in a High Risk Chinese Population. <i>Journal of Cancer</i> , 2019, 10, 3284-3290.	1.2	11
126	The value of magnetic resonance imaging in esophageal carcinoma: Tool or toy?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 101-107.	0.7	11



#	ARTICLE	IF	CITATIONS
127	A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators. <i>Cancer Medicine</i> , 2020, 9, 1430-1440.	1.3	11
128	Lymphocyte-monocyte ratio as a predictive marker for pathological complete response to neoadjuvant therapy in esophageal squamous cell carcinoma. <i>Translational Cancer Research</i> , 2020, 9, 3842-3853.	0.4	11
129	Three models that predict the efficacy of immunotherapy in Chinese patients with advanced non-small cell lung cancer. <i>Cancer Medicine</i> , 2021, 10, 6291-6303.	1.3	11
130	Late-Course Adaptive Adjustment Based on Metabolic Tumor Volume Changes during Radiotherapy May Reduce Radiation Toxicity in Patients with Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2017, 12, e0170901.	1.1	11
131	Efficacy of single-site radiotherapy plus PD-1 inhibitors vs PD-1 inhibitors for oligometastatic non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 1253-1261.	1.2	11
132	Efficacy of Immune Checkpoint Inhibitors in Patients With EGFR Mutated NSCLC and Potential Risk Factors Associated With Prognosis: A Single Institution Experience. <i>Frontiers in Immunology</i> , 2022, 13, 832419.	2.2	11
133	ERCC1 expression and tumor regression predict survival in esophageal squamous cell carcinoma patients receiving combined trimodality therapy. <i>Pathology Research and Practice</i> , 2014, 210, 656-661.	1.0	10
134	To Explore a Representative Hypoxic Parameter to Predict the Treatment Response and Prognosis Obtained by [18F]FMISO-PET in Patients with Non-small Cell Lung Cancer. <i>Molecular Imaging and Biology</i> , 2018, 20, 1061-1067.	1.3	10
135	Diagnostic and Predictive Value of Using RGD PET/CT in Patients with Cancer: A Systematic Review and Meta-Analysis. <i>BioMed Research International</i> , 2019, 2019, 1-15.	0.9	10
136	How breast cancer chemotherapy increases the risk of leukemia: Thoughts about a case of diffuse large B-cell lymphoma and leukemia after breast cancer chemotherapy. <i>Cancer Biology and Therapy</i> , 2016, 17, 125-128.	1.5	9
137	Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review. <i>Cancer Biology and Therapy</i> , 2017, 18, 279-284.	1.5	9
138	Clinical value of carcinoembryonic antigen for predicting the incidence of brain metastases and survival in small cell lung cancer patients treated with prophylactic cranial irradiation. <i>Cancer Management and Research</i> , 2018, Volume 10, 3199-3205.	0.9	9
139	End-of-life chemotherapy is associated with poor survival and aggressive care in patients with small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 1591-1599.	1.2	9
140	A prospective study on neoadjuvant chemoradiotherapy plus anti-EGFR monoclonal antibody followed by surgery for locally advanced cervical cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 3785-3792.	1.0	9
141	Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. <i>Cancer Management and Research</i> , 2019, Volume 11, 10083-10092.	0.9	9
142	Spatial Concordance of Tumor Proliferation and Accelerated Repopulation from Pathologic Images to [18F]Fluoro-3-Deoxythymidine PET Images: a Basic Study Guided for PET-Based Radiotherapy Dose Painting. <i>Molecular Imaging and Biology</i> , 2019, 21, 713-721.	1.3	9
143	What Is the Appropriate Clinical Target Volume for Esophageal Squamous Cell Carcinoma? Debate and Consensus Based on Pathological and Clinical Outcomes. <i>Journal of Cancer</i> , 2016, 7, 200-206.	1.2	8
144	Prognostic value of the standardized uptake value maximum change calculated by dual-time-point 18F-fluorodeoxyglucose positron emission tomography imaging in patients with advanced non-small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2016, 9, 2993.	1.0	8

#	ARTICLE	IF	CITATIONS
145	Out of the darkness and into the light: New strategies for improving treatments for locally advanced non-small cell lung cancer. <i>Cancer Letters</i> , 2018, 421, 59-62.	3.2	8
146	Magnetic resonance imaging evaluation of treatment efficacy and prognosis for brain metastases in lung cancer patients after radiotherapy: A preliminary study. <i>Thoracic Cancer</i> , 2018, 9, 865-873.	0.8	8
147	Potential of Gd-EOB-DTPA as an imaging biomarker for liver injury estimation after radiation therapy. <i>Hepatobiliary and Pancreatic Diseases International</i> , 2019, 18, 354-359.	0.6	8
148	Proposed revision of N categories to the 8th edition of the AJCC $\hat{\text{c}}$ TNM staging system for non $\hat{\text{c}}$ surgical esophageal squamous cell cancer. <i>Cancer Science</i> , 2019, 110, 717-725.	1.7	8
149	Preparation study of indocyanine green-rituximab: A new receptor-targeted tracer for sentinel lymph node in breast cancer. <i>Oncotarget</i> , 2016, 7, 47526-47535.	0.8	8
150	$^{18}\text{F}$ -deoxyglucose positron emission tomography/computed tomography to predict local failure in esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 34498-34506.	0.8	8
151	Increased hippocampal TrkA expression ameliorates cranial radiation $\hat{\text{c}}$ induced neurogenesis impairment and cognitive deficit via PI3K/AKT signaling. <i>Oncology Reports</i> , 2020, 44, 2527-2536.	1.2	8
152	Comprehensive Next-Generation Sequencing Reveals Novel Predictive Biomarkers of Recurrence and Thoracic Toxicity Risks After Chemoradiation Therapy in Limited Stage Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1165-1176.	0.4	8
153	Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more. <i>Future Oncology</i> , 2018, 14, 2131-2138.	1.1	7
154	Prognostic value of monocarboxylate transporter 4 in patients with esophageal squamous cell carcinoma. <i>Oncology Reports</i> , 2018, 40, 2906-2915.	1.2	7
155	$\hat{\text{c}}$ Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study $\hat{\text{c}}$ . <i>OncoTargets and Therapy</i> , 2019, Volume 12, 1681-1689.	1.0	7
156	Combination therapy. <i>Medicine (United States)</i> , 2019, 98, e18030.	0.4	7
157	Hyper-progressive disease in a patient with advanced non-small cell lung cancer on immune checkpoint inhibitor therapy: A case report and literature review. <i>Lung Cancer</i> , 2020, 139, 18-21.	0.9	7
158	Nanoparticle albumin $\hat{\text{c}}$ bound paclitaxel in elder patients with advanced squamous non $\hat{\text{c}}$ small $\hat{\text{c}}$ cell lung cancer: A retrospective study. <i>Cancer Medicine</i> , 2020, 9, 1365-1373.	1.3	7
159	Should all breast cancer patients with four or more positive lymph nodes who underwent modified radical mastectomy be treated with postoperative radiotherapy? A population-based study. <i>Oncotarget</i> , 2016, 7, 75492-75502.	0.8	7
160	Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy. <i>BMC Gastroenterology</i> , 2022, 22, 211.	0.8	7
161	The role of multi-omics in the diagnosis of COVID-19 and the prediction of new therapeutic targets. <i>Virulence</i> , 2022, 13, 1101-1110.	1.8	7
162	Anatomic distribution of supraclavicular lymph node in patients with esophageal cancer. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 5803-5808.	1.0	6

#	ARTICLE	IF	CITATIONS
163	Efficacy of cisplatin/pemetrexed with bevacizumab to treat advanced lung adenocarcinoma with different drive genes: case report and literature review. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4639-4644.	1.0	6
164	<sup>18</sup> F- $\alpha$ alfatide positron emission tomography may predict anti-angiogenic responses. <i>Oncology Reports</i> , 2018, 40, 2896-2905.	1.2	6
165	Previous Radiotherapy Increases the Efficacy of IL-2 in Malignant Pleural Effusion: Potential Evidence of a Radio-Memory Effect?. <i>Frontiers in Immunology</i> , 2018, 9, 2916.	2.2	6
166	Effectiveness of temozolomide combined with whole brain radiotherapy for non-small cell lung cancer brain metastases. <i>Thoracic Cancer</i> , 2018, 9, 1121-1128.	0.8	6
167	Local therapy combined with chemotherapy versus chemotherapy for postoperative oligometastatic non-small-cell lung cancer. <i>Future Oncology</i> , 2019, 15, 1593-1603.	1.1	6
168	Case Report: Transformation From Cold to Hot Tumor in a Case of NSCLC Neoadjuvant Immunochemotherapy Pseudoprogression. <i>Frontiers in Immunology</i> , 2021, 12, 633534.	2.2	6
169	Long non-coding RNA transcribed from pseudogene PPIAP43 is associated with radiation sensitivity of small cell lung cancer cells. <i>Oncology Letters</i> , 2019, 18, 4583-4592.	0.8	6
170	An in silico mechanistic insight into HDAC8 activation facilitates the discovery of new small-molecule activators. <i>Bioorganic and Medicinal Chemistry</i> , 2020, 28, 115607.	1.4	5
171	Enhanced radiosensitizing by sodium glycididazole in a recurrent esophageal carcinoma tumor model. <i>Oncotarget</i> , 2017, 8, 63871-63880.	0.8	5
172	High expression level of peptidylprolyl isomerase A is correlated with poor prognosis of liver hepatocellular carcinoma. <i>Oncology Letters</i> , 2019, 18, 4691-4702.	0.8	5
173	Genomic Correlates of Unfavorable Outcome in Locally Advanced Cervical Cancer Treated with Neoadjuvant Chemoradiation. <i>Cancer Research and Treatment</i> , 2022, 54, 1209-1218.	1.3	5
174	Risk of brain metastasis reduced after erlotinib treatment in advanced pulmonary adenocarcinoma patients with sensitive EGFR mutation. <i>OncoTargets and Therapy</i> , 2016, 9, 671.	1.0	4
175	Orbital metastasis as the initial presentation of lung adenocarcinoma: a case report. <i>OncoTargets and Therapy</i> , 2016, 9, 2743.	1.0	4
176	Stereotactic Comparison Study of <sup>18</sup> F-Alfatide and <sup>18</sup> F-FDG PET Imaging in an LLC Tumor-Bearing C57BL/6 Mouse Model. <i>Scientific Reports</i> , 2016, 6, 28757.	1.6	4
177	Current progress and outcomes of clinical trials on using epidermal growth factor receptor tyrosine kinase inhibitor therapy in non-small cell lung cancer patients with brain metastases. <i>Chronic Diseases and Translational Medicine</i> , 2017, 3, 221-229.	0.9	4
178	Efficacy of EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients harboring different types of EGFR mutations: A retrospective analysis. <i>Current Medical Science</i> , 2017, 37, 864-872.	0.7	4
179	Surgery of primary tumor improves the survival of newly diagnosed metastatic melanoma: a population-based, propensity-matched study. <i>Cancer Management and Research</i> , 2018, Volume 11, 339-346.	0.9	4
180	Great efficacy of bevacizumab plus erlotinib for leptomeningeal metastases from non-small cell lung cancer with initially positive EGFR mutation: a case report. <i>Cancer Biology and Therapy</i> , 2018, 19, 1073-1077.	1.5	4

#	ARTICLE	IF	CITATIONS
181	<sup>18</sup> 18</sup>F-fluorodeoxyglucose positron emission tomography predicts lymph node responses to definitive chemoradiotherapy in esophageal squamous cell carcinoma patients. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 4345-4353.	1.0	4
182	A nomogram for the predicting of survival in patients with esophageal squamous cell carcinoma undergoing definitive chemoradiotherapy. <i>Annals of Translational Medicine</i> , 2021, 9, 233-233.	0.7	4
183	Identification of risk factors and the pattern of lower cervical lymph node metastasis in esophageal cancer: implications for radiotherapy target delineation. <i>Oncotarget</i> , 2017, 8, 43389-43396.	0.8	4
184	A missense variant in EZH2 is associated with colorectal cancer risk in a Chinese population. <i>Oncotarget</i> , 2017, 8, 94738-94742.	0.8	4
185	Survival prediction models for patients with anal carcinoma receiving definitive chemoradiation: A populationâ€based study. <i>Oncology Letters</i> , 2020, 19, 1443-1451.	0.8	4
186	The effect of TKI therapy and chemotherapy treatment delivery sequence on total progressionâ€free survival in patients with advanced EGFRâ€mutated NSCLC. <i>Oncology Letters</i> , 2020, 20, 391-400.	0.8	4
187	IDH1 Mutation Induces HIF-1 $\alpha$ and Confers Angiogenic Properties in Chondrosarcoma JJ012 Cells. <i>Disease Markers</i> , 2022, 2022, 1-11.	0.6	4
188	Mapping patterns of nodal metastases in esophageal carcinoma: rethinking the clinical target volume for supraclavicular nodal irradiation. <i>Journal of Thoracic Disease</i> , 2016, 8, 3132-3138.	0.6	3
189	SRS versus WBRT for resected brain metastases. <i>Lancet Oncology</i> , The, 2017, 18, e559.	5.1	3
190	Local ablative therapy with or without chemotherapy for non-small-cell lung cancer patients with postoperative oligometastases. <i>Cancer Management and Research</i> , 2018, Volume 10, 6421-6429.	0.9	3
191	<p>Axillary management still needed for patients with sentinel node micrometastases</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 2097-2100.	0.9	3
192	Safety of thoracic radiotherapy after PDâ€(L)1 inhibitor treatment in patients with lung cancer. <i>Cancer Medicine</i> , 2021, 10, 8518-8529.	1.3	3
193	Inhibition of janus kinase 2 by compound AG490 suppresses the proliferation of MDA-MB-231 cells via up-regulating SARI (suppressor of AP-1, regulated by IFN). <i>Iranian Journal of Basic Medical Sciences</i> , 2015, 18, 599-603.	1.0	3
194	High level of programmed death ligand 1 (PD-L1) predicts longer survival in patients with resectable small cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2018, 11, 2675-2682.	0.5	3
195	Tumor angiogenesis at baseline identified by 18F-Alfatide II PET/CT may predict survival among patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy. <i>Journal of Translational Medicine</i> , 2022, 20, 63.	1.8	3
196	Concurrent Chemoradiotherapy Increases the Levels of Soluble Immune Checkpoint Proteins in Patients with Locally Advanced Cervical Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-8.	0.9	3
197	High-dose OxyContin to treat pain associated with bone metastasis in patients with small-cell lung cancer: a case study report. <i>Drug Design, Development and Therapy</i> , 2016, 10, 383.	2.0	2
198	To Find a Better Dosimetric Parameter in the Predicting of Radiation-Induced Lung Toxicity Individually: Ventilation, Perfusion or CT based. <i>Scientific Reports</i> , 2017, 7, 44646.	1.6	2

#	ARTICLE	IF	CITATIONS
199	Internal mammary sentinel lymph node biopsy: An effective way to search benefit patients and guide internal mammary chain irradiation. <i>Breast</i> , 2017, 33, 204-205.	0.9	2
200	Is it time to convert the frequency of radiotherapy in small-cell lung cancer?. <i>Lancet Oncology</i> , The, 2017, 18, e553.	5.1	2
201	Effects of respiratory motion on volumetric and positional difference of GTV in lung cancer based on 3DCT and 4DCT scanning. <i>Oncology Letters</i> , 2019, 17, 2388-2392.	0.8	2
202	The flow-metabolism ratio might predict treatment response and survival in patients with locally advanced esophageal squamous cell carcinoma. <i>EJNMMI Research</i> , 2020, 10, 57.	1.1	2
203	Safety and efficacy of SHR-1316 combined with chemotherapy and sequential chest radiotherapy as first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): The results from a phase II single-arm trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8563-8563.	0.8	2
204	Reversion of erlotinib-acquired resistance twice by chemotherapy. <i>Cancer Biology and Therapy</i> , 2014, 15, 172-177.	1.5	1
205	Postoperative radiation therapy of pT2-3N0M0 esophageal carcinoma—a review. <i>Tumor Biology</i> , 2016, 37, 14443-14450.	0.8	1
206	Unusual delayed presentation of diaphragmatic hernia complicated by transverse colon and total small-bowel obstruction after postoperative chemotherapy of esophageal cancer. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 691-695.	0.9	1
207	Subclinical Lesions of the Primary Clinical Target Volume Margin in Esophageal Squamous Cell Carcinoma and Association With FDG PET/CT. <i>Frontiers in Oncology</i> , 2019, 9, 336.	1.3	1
208	A 4-month-old boy with gastrointestinal stromal tumor of mesocolon. <i>Cancer Biology and Therapy</i> , 2019, 20, 8-14.	1.5	1
209	Left Ventricular Systolic Dysfunction Is a Possible Independent Risk Factor of Radiation Pneumonitis in Locally Advanced Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2019, 9, 1511.	1.3	1
210	Prediction of the effects of radiation therapy in esophageal cancer using diffusion and perfusion MRI. <i>Cancer Science</i> , 2021, 112, 5046-5054.	1.7	1
211	Comparison of different width detector on the gross tumor volume delineation of the solitary pulmonary lesion. <i>Journal of Cancer Research and Therapeutics</i> , 2017, 13, 693.	0.3	1
212	Kinetic change of serum carcinoembryonic antigen can early predict progression in patients with metastatic non-small cell lung cancer during maintenance therapy with bevacizumab plus pemetrexed. <i>Oncotarget</i> , 2017, 8, 74910-74916.	0.8	1
213	Precision regimen for personalized pancreatic cancer therapy. <i>Precision Radiation Oncology</i> , 2017, 1, 44-45.	0.4	0
214	The feasibility of non-contrast enhanced plus contrast-enhanced computed tomography in discriminating invasive pure ground-glass opacity from pre-invasive pure ground-glass opacity. <i>Journal of Cardiothoracic Surgery</i> , 2020, 15, 162.	0.4	0
215	Elevated serum carcinoembryonic antigen and prediction of poor survival of patients with small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e18561-e18561.	0.8	0
216	Stereotactic comparison study of 18F-Alfatide and 18F-FDG PET imaging in LLC tumor-bearing C57BL/6 mice model.. <i>Journal of Clinical Oncology</i> , 2016, 34, e20070-e20070.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Inhibition of hypoxia-inducible factor-1 $\alpha$ by PX-478 as a potential targeted therapy in ESCC.. Journal of Clinical Oncology, 2017, 35, e14083-e14083.	0.8	0
218	Prognostic significance of the lymphocyte-to-monocyte ratio and the tumor-infiltrating lymphocyte to tumor-associated macrophage ratio in patients with stage T3N0M0 esophageal squamous cell carcinoma.. Journal of Clinical Oncology, 2017, 35, e15602-e15602.	0.8	0
219	Spatial concordance of tumor proliferation and accelerated repopulation from pathologic images to 18F-FLT PET images.. Journal of Clinical Oncology, 2017, 35, e23100-e23100.	0.8	0
220	Association of CD8+/FOXP3+ ratio and PD-L1 expression with survival in pT3N0M0 stage esophageal squamous cell cancer.. Journal of Clinical Oncology, 2017, 35, e15517-e15517.	0.8	0
221	A prospective study on neoadjuvant chemoradiotherapy plus nimotuzumab followed by surgery for patients with advanced cervical cancer.. Journal of Clinical Oncology, 2017, 35, e17000-e17000.	0.8	0
222	A prognostic score model to determine which breast cancer patients with 1-3 positive lymph nodes after modified radical mastectomy should receive radiotherapy. Oncotarget, 2018, 9, 385-393.	0.8	0
223	Association between heart dosimetric parameters, cardiac events and overall survival for patients with stage III esophageal cancer treated with definitive radiotherapy.. Journal of Clinical Oncology, 2019, 37, e15561-e15561.	0.8	0
224	Apatinib in the treatment of non-operable or advanced gastric cancer: Evidence of efficacy and safety in a real-world study.. Journal of Clinical Oncology, 2019, 37, e15515-e15515.	0.8	0
225	Interleukin-2 boosts local and abscopal antitumor effect of radiotherapy combined with anti-PD-1: A translational research from clinical radio-memory effect.. Journal of Clinical Oncology, 2019, 37, e14244-e14244.	0.8	0
226	Primary tumor location as an important predictor for survival in pulmonary adenocarcinoma.. Journal of Clinical Oncology, 2019, 37, e20000-e20000.	0.8	0
227	Dosimetric and radiobiological comparison of external beam radiotherapy using simultaneous integrated boost technique for esophageal cancer in different location.. Journal of Clinical Oncology, 2019, 37, e15505-e15505.	0.8	0
228	Derived neutrophil-to-lymphocyte ratio and platelet to lymphocyte ratio as a prognostic marker for patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy.. Journal of Clinical Oncology, 2019, 37, e15575-e15575.	0.8	0
229	Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): Subgroup analysis of the TAIL study.. Journal of Clinical Oncology, 2020, 38, e21628-e21628.	0.8	0
230	Prognostic biomarker candidates of neoadjuvant chemotherapy for luminal B-positive locally advanced breast cancer.. Journal of Clinical Oncology, 2020, 38, e12638-e12638.	0.8	0
231	Screening of potential genes and transcription factors involved in post-radiation cognitive dysfunction in mice via bioinformatics. Translational Cancer Research, 2020, 9, 6383-6391.	0.4	0
232	Progress of radiation oncology: known and unknown. Chinese Medical Journal, 2014, 127, 2173-9.	0.9	0
233	Abstract 6114: Prognostic value of the tumor-infiltrating lymphocytes in Miller-Payne grade 4 triple-negative breast cancer following neoadjuvant chemotherapy. Cancer Research, 2022, 82, 6114-6114.	0.4	0